Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Boston and Seattle football fans beware! Cities with teams in the Super Bowl see a big spike in flu deaths, according to a new Tulane University study.
Earlier this month, the Centers for Disease Control and Prevention recommended the use of antiviral drugs to help treat influenza, in a year when the available vaccine is not a good match for the current strain.
In baseball, three strikes and you're out. The most common annual vaccine targets three strains of flu virus. This year, two vaccine strains are spot on and successfully matched. One strain is partially mismatched, but still believed to offer partial coverage for that strain. The current flu vaccine is still in the game and, more importantly, keeping people well and on the playing field, says a Loyola University Medical Center infectious disease specialist.
Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.
Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.
The flu, or seasonal influenza virus, is extremely unpredictable. Its severity can vary widely from one season to the next depending on many things, including the strains of flu spreading, availability of vaccines, how many people get vaccinated and how well the flu vaccine is matched to the flu viruses circulating each season.
As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.
Seasonal flu vaccines may protect individuals not only against the strains of flu they contain but also against many additional types, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.
Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information.
Influenza vaccination coverage estimates show an encouraging upward trend overall, but coverage among healthy 18 to 64 year-olds has yet to top 40 percent, according to new data announced at a news conference held today by the National Foundation for Infectious Diseases.
Everyone knows that the best way to avoid the flu is by getting an annual flu shot. But a trip to your physician every autumn for the vaccination can help you avoid much more than the dreaded flu bug. "At the doctor's office, the focus is on you and what is going on with your health. This is your time to talk about concerns to improve your well-being beyond the flu season," says Jorge Parada, MD, MPH, the medical director of the Infection Prevention and Control Program at Loyola University Health System.
A study led by St. Jude Children's Research Hospital scientists found the avian influenza A H3N8 virus that killed harbor seals along the New England coast can spread through respiratory droplets and poses a threat to humans.
This influenza season was particularly hard on younger- and middle-age adults, the Centers for Disease Control and Prevention reported in today's Morbidity and Mortality Weekly Report.
Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.
NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.
A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.
A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.
Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.
NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.